A randomized, double-blind, placebo controlled, two period crossover study to investigate the pharmacokinetics, tolerability and cognitive effects of 8 days dosing of CNV1014802 in healthy young versus elderly male and female subjects. Treatment periods will be separated by 13 days. The primary outcome measures are pharmacokinetics (PK) and tolerability.
This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been acquired by Biogen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
32
Parexel International
London, United Kingdom
Maximum Concentration
Time frame: 9 days
Area under the concentration curve
Time frame: 9 days
Minimum concentration
Time frame: 9 days
Frequency of adverse events
Time frame: 9 days
Change in vital signs compared to baseline
Time frame: 9 days
Change in 12-lead ECG parameters compared to baseline
Time frame: 9 days
Change in safety lab parameters compared to baseline
Time frame: 9 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.